» Articles » PMID: 38356877

Resource Use and Disease Severity of Children Hospitalized for COVID-19 Versus Multisystem Inflammatory Syndrome in Children (MIS-C) in Canada

Abstract

Background: Direct comparisons of paediatric hospitalizations for acute coronavirus disease 2019 (COVID-19) and multisystem inflammatory syndrome in children (MIS-C) can inform health system planning. We describe the absolute and relative hospital burden of acute paediatric COVID-19 and MIS-C in Canada.

Methods: This national prospective study was conducted via the Canadian Paediatric Surveillance Program from March 2020-May 2021. Children younger than 18 years old and hospitalized for acute COVID-19 or MIS-C were included in the analysis. Outcomes included supplemental oxygen (low-flow oxygen or high-flow nasal cannula), ventilation (non-invasive or conventional mechanical), vasopressors, paediatric intensive care unit (PICU) admission, or death. Adjusted risk differences (aRD) and 95% confidence intervals (CI) were calculated to identify factors associated with each diagnosis.

Results: Overall, we identified 330 children hospitalized for acute COVID-19 (including five deaths) and 208 hospitalized for MIS-C (including zero deaths); PICU admission was required for 49.5% of MIS-C hospitalizations versus 18.2% of acute COVID-19 hospitalizations (aRD 20.3; 95% CI, 9.9-30.8). Resource use differed by age, with children younger than one year hospitalized more often for acute COVID-19 (aRD 43.4% versus MIS-C; 95% CI, 37.7-49.1) and more children 5-11 years hospitalized for MIS-C (aRD 38.9% vs. acute COVID-19; 95% CI, 31.0-46.9).

Conclusion: While there were more hospitalizations and deaths from acute paediatric COVID-19, MIS-C cases were more severe, requiring more intensive care and vasopressor support. Our findings suggest that both acute COVID-19 and MIS-C should be considered when assessing the overall burden of severe acute respiratory syndrome coronavirus 2 in hospitalized children.

References
1.
Martin B, DeWitt P, Russell S, Anand A, Bradwell K, Bremer C . Characteristics, Outcomes, and Severity Risk Factors Associated With SARS-CoV-2 Infection Among Children in the US National COVID Cohort Collaborative. JAMA Netw Open. 2022; 5(2):e2143151. PMC: 8826172. DOI: 10.1001/jamanetworkopen.2021.43151. View

2.
Zambrano L, Newhams M, Olson S, Halasa N, Price A, Boom J . Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021. MMWR Morb Mortal Wkly Rep. 2022; 71(2):52-58. PMC: 8757620. DOI: 10.15585/mmwr.mm7102e1. View

3.
Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P . Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020; 395(10237):1607-1608. PMC: 7204765. DOI: 10.1016/S0140-6736(20)31094-1. View

4.
Flood J, Shingleton J, Bennett E, Walker B, Amin-Chowdhury Z, Oligbu G . Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS): Prospective, national surveillance, United Kingdom and Ireland, 2020. Lancet Reg Health Eur. 2021; 3:100075. PMC: 8132575. DOI: 10.1016/j.lanepe.2021.100075. View

5.
Olson S, Newhams M, Halasa N, Price A, Boom J, Sahni L . Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12-18 Years - United States, June-September 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(42):1483-1488. PMC: 9361838. DOI: 10.15585/mmwr.mm7042e1. View